Research Progress on New Drugs for Thrombosis Prevention and Treatment Based on Coagulation Factor Ⅺ
10.3870/j.issn.1004-0781.2025.03.020
- VernacularTitle:基于凝血因子Ⅺ的血栓防治新药研究进展
- Author:
Yang LEI
1
;
Yuan BIAN
;
Jianting LIAO
;
Gang LI
;
Liuyun WU
;
Xingyue ZHENG
;
Lian LI
;
Lizhu HAN
;
Qinan YIN
Author Information
1. 四川省医学科学院·四川省人民医院药学部,成都 610072
- Publication Type:Journal Article
- Keywords:
Coagulation factor Ⅺ;
Anticoagulant drugs;
Thrombosis;
Bleeding
- From:
Herald of Medicine
2025;44(3):452-458
- CountryChina
- Language:Chinese
-
Abstract:
Anticoagulants are widely used in the prevention and treatment of thromboembolism.Existing anticoagulants share the common feature of antagonizing or blocking critical steps in the coagulation cascade,which also increases the risk of bleeding.Studies have indicated that factor Ⅺ inhibitors represent a potential therapeutic option for balancing thrombosis and bleeding risks.In recent years,various factor Ⅺ inhibitors,including antisense oligonucleotides(ASOs),monoclonal antibodies,synthetic small molecules,natural peptides,and aptamers,have been extensively researched as potentially exploitable anticoagu-lants.Research findings also suggest that factor Ⅺ inhibitors can reduce bleeding risks while ensuring anticoagulant efficacy,ex-hibiting potential for thrombosis prevention and treatment in patient populations such as those with end-stage renal disease,non-cardioembolic ischemic stroke,and acute coronary syndrome.This article reviewed the mechanisms of action,drug classes,pharma-cological characteristics,and clinical research progress of factor Ⅺ inhibitors,aiming to provide insights into the development of new anticoagulants and clinical anticoagulant therapies.
